J. Nitiss

发表

Mutation of a Conserved Serine Residue in a Quinolone-resistant Type II Topoisomerase Alters the Enzyme-DNA and Drug Interactions*

Y. Pommier, D. Strumberg, M. Nicklaus, 1999, The Journal of Biological Chemistry.

A Mutant Yeast Topoisomerase II (top2G437S) with Differential Sensitivity to Anticancer Drugs in the Presence and Absence of ATP*

N. Osheroff, M. Sabourin, J. Nitiss, 1998, The Journal of Biological Chemistry.

Thioguanine substitution alters DNA cleavage mediated by topoisomerase II

M. Relling, Xiangjun Cai, X. Cai, 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

Activation of the Unfolded Protein Response Is Necessary and Sufficient for Reducing Topoisomerase IIα Protein Levels and Decreasing Sensitivity to Topoisomerase-Targeted Drugs

L. Hendershot, M. Mann, J. Nitiss, 2005, Molecular Pharmacology.

Biochemical and Proteomics Approaches to Characterize Topoisomerase IIα Cysteines and DNA as Targets Responsible for Cisplatin-Induced Inhibition of Topoisomerase IIα

W. Ens, K. Standing, O. Krokhin, 2005, Molecular Pharmacology.

Topoisomerase II Inhibitors: Chemical Biology

N. Osheroff, J. Nitiss, K. Bahmed, 2012 .

Understanding the action of drugs targeting TOP2: Yeast based systems for unraveling drug mechanisms

M. Malik, J. Nitiss, 2003 .

DNA topoisomerase II is the molecular target of bisdioxopiperazine derivatives ICRF-159 and ICRF-193 in Saccharomyces cerevisiae.

J. Wang, T. Andoh, M. Hamatake, 1995, Cancer research.

Yeast topoisomerase II mutants resistant to anti-topoisomerase agents: identification and characterization of new yeast topoisomerase II mutants selected for resistance to etoposide.

M. Jannatipour, Y. Liu, J. Nitiss, 1994, Cancer research.

Yeast as a genetic model system for studying topoisomerase inhibitors.

J. Nitiss, 1994, Advances in pharmacology.

Mutations of human topoisomerase IIα affecting multidrug resistance and sensitivity

T. Hsieh, Leroy F. Liu, Huimin Wang, 1999 .

A Mutation in Yeast TOP2 Homologous to a Quinolone-resistant Mutation in Bacteria

N. Osheroff, S. Elsea, J. Nitiss, 1995, The Journal of Biological Chemistry.

Meiosis can induce recombination in rad52 mutants of Saccharomyces cerevisiae.

M. Resnick, J. Nitiss, R. Malone, 1986, Genetics.

DNA polymerases, deoxyribonucleases, and recombination during meiosis in Saccharomyces cerevisiae

M. Resnick, T. Chow, A. Sugino, 1984, Molecular and cellular biology.

Using yeast to study resistance to topoisomerase II-targeting drugs

J. Nitiss, 2004, Cancer Chemotherapy and Pharmacology.

Topoisomerase I-mediated cytotoxicity of N-methyl-N'-nitro-N-nitrosoguanidine: trapping of topoisomerase I by the O6-methylguanine.

Y. Pommier, P. Pourquier, A. Pegg, 2001, Cancer research.

Aclacinomycin A stabilizes topoisomerase I covalent complexes.

Y. Pommier, P. Pourquier, J. Nitiss, 1997, Cancer research.

DNA Topoisomerases in DNA Repair and DNA Damage Tolerance

J. Nitiss, 1998 .

Isolation and Characterization of mAMSA-hypersensitive Mutants

J. Nitiss, Anna T. Rogojina, A. Rogojina, 2008, Journal of Biological Chemistry.

A Novel Mechanism of Cell Killing by Anti-topoisomerase II Bisdioxopiperazines*

N. Osheroff, M. Sehested, L. Jensen, 2000, The Journal of Biological Chemistry.

High-Level Resistance to Bisdioxopiperazines Catalytic Inhibitor ICRF-159 : A Tyr 49 Phe Mutation Confers Chinese Hamster Ovary Cells Resistant to the Topoisomerase II Updated

S. Kenwrick, L. Jensen, Andrew, 2006 .

Aclacinomycin A Stabilizes Topoisomerase I Covalent Complexes1

Y. Pommier, P. Pourquier, J. Nitiss, 2006 .

Probing the role of linker substituents in bisdioxopiperazine analogs for activity against wild-type and mutant human topoisomerase II alpha.

M. Sehested, L. Jensen, A. Renodon-Cornière, 2003, Molecular pharmacology.

N‐terminal and core‐domain random mutations in human topoisomerase II α conferring bisdioxopiperazine resistance

M. Sehested, L. Jensen, P. B. Jensen, 2000, FEBS letters.

Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.

S. Kenwrick, M. Sehested, L. Jensen, 1998, Cancer research.

A Yeast Type II Topoisomerase Selected for Resistance to Quinolones

N. Osheroff, S. Elsea, J. Nitiss, 1995, The Journal of Biological Chemistry.

DNA Repair Functions That Control Sensitivity to Topoisomerase-Targeting Drugs

M. Malik, J. Nitiss, 2004, Eukaryotic Cell.

Resistance to Topoisomerase-Targeting Agents

K. C. Nitiss, J. Nitiss, 2002 .

A Mutation in Yeast Topoisomerase II That Confers Hypersensitivity to Multiple Classes of Topoisomerase II Poisons*

J. Dong, J. Nitiss, J. Walker, 2000, The Journal of Biological Chemistry.

Molecular Analysis of Yeast and Human Type II Topoisomerases

K. Kohn, Y. Pommier, D. Strumberg, 1999, The Journal of Biological Chemistry.

Antifungal Activity of Eupolauridine and Its Action on DNA Topoisomerases

L. Walker, Shabana I. Khan, A. Nimrod, 2002, Antimicrobial Agents and Chemotherapy.

Requirements for MRN endonuclease processing of topoisomerase II-mediated DNA damage in mammalian cells

Y. Pommier, Eroica Soans, Yilun Sun, 2022, Frontiers in Molecular Biosciences.

Etoposide: a Genetic System for Determining the Targets of Temperature Dependent Drug Resistance on Amsacrine and a Temperature Sensitive Topoisomerase Ii Allele Confers Updated Version Citing Articles E-mail Alerts a Temperature Sensitive Topoisomerase Ii Alã-eleconfers Temperature Dependent Drug R

Y., J. Nitiss, Y.X. Liu, 2022 .

Amsacrine and etoposide hypersensitivity of yeast cells overexpressing DNA topoisomerase II.

J. Wang, M. Jannatipour, P. Harbury, 1992, Cancer research.

Targeting DNA topoisomerase II in cancer chemotherapy

J. Nitiss, 2009, Nature Reviews Cancer.

Etoposide-induced DNA damage is increased in p53 mutants: identification of ATR and other genes that influence effects of p53 mutations on Top2-induced cytotoxicity

Scott E. Martin, Eugen C. Buehler, M. A. Resnick, 2022, Oncotarget.

Topoisomerase Assays

N. Maizels, Yilun Sun, K. C. Nitiss, 2021, Current protocols.

Proteolytic Degradation of Topoisomerase II (Top2) Enables the Processing of Top2·DNA and Top2·RNA Covalent Complexes by Tyrosyl-DNA-Phosphodiesterase 2 (TDP2)* ♦

Y. Pommier, Shar-yin N. Huang, C. Marchand, 2014, The Journal of Biological Chemistry.

Tdp2: A Means to Fixing the Ends

K. C. Nitiss, J. Nitiss, 2013, PLoS genetics.

Topoisomerase Assays

Eroica Soans, J. Nitiss, Aman Seth, 2012, Current protocols in pharmacology.

UnTTrapping the ends: A new player in overcoming protein linked DNA damage

K. C. Nitiss, J. Nitiss, K. Bahmed, 2010, Cell Research.

Using Yeast to Understand Drugs that Target Topoisomerases a

Junfang Zhou, J. Nitiss, A. Rose, 1996, Annals of the New York Academy of Sciences.

Assessing Sensitivity to Antibacterial Topoisomerase II Inhibitors

L. Zechiedrich, H. Hiasa, J. Nitiss, 2007, Current protocols in pharmacology.

DNA topoisomerases in cancer chemotherapy: using enzymes to generate selective DNA damage.

J. Nitiss, 2002, Current opinion in investigational drugs.

Cytotoxicity of quinolones toward eukaryotic cells. Identification of topoisomerase II as the primary cellular target for the quinolone CP-115,953 in yeast.

N. Osheroff, S. Elsea, J. Nitiss, 1992, The Journal of biological chemistry.

DNA topoisomerases as targets for the anticancer drug TAS-103: primary cellular target and DNA cleavage enhancement.

N. Osheroff, D. Burden, J. Fortune, 1999, Biochemistry.

A Mutation in Human Topoisomerase II α Whose Expression Is Lethal in DNA Repair-deficient Yeast Cells*

M. Sehested, L. Jensen, T. Hsieh, 2004, Journal of Biological Chemistry.

Overexpression of Type I Topoisomerases Sensitizes Yeast Cells to DNA Damage*

K. C. Nitiss, J. Nitiss, A. Rose, 2001, The Journal of Biological Chemistry.

Roles of eukaryotic topoisomerases in transcription, replication and genomic stability

Y. Pommier, Yilun Sun, Shar-yin N. Huang, 2016, Nature Reviews Molecular Cell Biology.

DNA topoisomerase II and its growing repertoire of biological functions

J. Nitiss, 2009, Nature Reviews Cancer.

Investigating the biological functions of DNA topoisomerases in eukaryotic cells.

J. Nitiss, 1998, Biochimica et biophysica acta.

Biologically active carbazole alkaloids from Murraya koenigii.

M. Nair, G. Strasburg, D. Dewitt, 1999, Journal of agricultural and food chemistry.

ATP-independent DNA strand transfer catalyzed by protein(s) from meiotic cells of the yeast Saccharomyces cerevisiae.

M. Resnick, A. Sugino, J. Nitiss, 1988, Proceedings of the National Academy of Sciences of the United States of America.

DNA topoisomerase-targeting antitumor drugs can be studied in yeast.

J. Wang, James C. Wang, J. Nitiss, 1988, Proceedings of the National Academy of Sciences of the United States of America.

Metabolites of daidzein and genistein and their biological activities.

M. Nair, J. Nitiss, Y. Chang, 1995, Journal of natural products.

A Mutation in Escherichia coli DNA Gyrase Conferring Quinolone Resistance Results in Sensitivity to Drugs Targeting Eukaryotic Topoisomerase II

Y. Pommier, E. L. Zechiedrich, D. Strumberg, 2004, Antimicrobial Agents and Chemotherapy.

Interaction model for anthracycline activity against DNA topoisomerase II.

S. Moro, G. Capranico, M. Palumbo, 2004, Biochemistry.

A complex suite of loci and elements in eukaryotic type II topoisomerases determine selective sensitivity to distinct poisoning agents

Afif F. Bandak, J. Berger, A. S. Lee, 2019, Nucleic acids research.

Aberrant Topoisomerase-1-DNA Lesions are Pathogenic in Neurodegenerative Genome Instability Syndromes

Yang Li, Jingfeng Zhao, J. Petrini, 2014, Nature Neuroscience.

Trapped topoisomerase II initiates formation of de novo duplications via the nonhomologous end-joining pathway in yeast

J. Berger, Yilun Sun, S. Jinks-Robertson, 2020, Proceedings of the National Academy of Sciences.

DNA Damage by an essential enzyme: A delicate balance act on the tightrope.

L. Hanakahi, K. C. Nitiss, J. Nitiss, 2019, DNA repair.

TDP1 is required for efficient non-homologous end joining in human cells.

L. Hanakahi, K. C. Nitiss, J. Nitiss, 2017, DNA repair.

Title : TDP 1 promotes assembly of non-homologous end joining protein complexes on DNA

Karin, S. Katyal, L. Hanakahi, 2015 .

A temperature sensitive topoisomerase II allele confers temperature dependent drug resistance on amsacrine and etoposide: a genetic system for determining the targets of topoisomerase II inhibitors.

J. Nitiss, Y. Hsiung, Y. X. Liu, 1993, Cancer Research.

Repair of Topoisomerase II-Mediated DNA Damage: Fixing DNA Damage Arising from a Protein Covalently Trapped on DNA

Eroica Soans, K. C. Nitiss, J. Nitiss, 2012 .

Using Yeast Tools to Dissect the Action of Anticancer Drugs: Mechanisms of Enzyme Inhibition and Cell Killing by Agents Targeting DNA Topoisomerases

K. C. Nitiss, J. Nitiss, A. Rogojina, 2007 .

Tyrosyl-DNA phosphodiesterase (Tdp1) participates in the repair of Top2-mediated DNA damage.

S. White, M. Malik, K. C. Nitiss, 2006, Proceedings of the National Academy of Sciences of the United States of America.

Roles of nonhomologous end-joining pathways in surviving topoisomerase II–mediated DNA damage

M. Malik, K. C. Nitiss, J. Nitiss, 2006, Molecular Cancer Therapeutics.

Yeast recombination pathways triggered by topoisomerase II-mediated DNA breaks.

N. Osheroff, M. Sabourin, K. Tatebayashi, 2003, Nucleic acids research.

DNA Topoisomerase II as a Target for Cancer Chemotherapy

J. Nitiss, Jerrylaine V. Walker, 2002, Cancer investigation.

Antitopoisomerase drug action and resistance.

W. T. Beck, J. Nitiss, 1996, European journal of cancer.

Roles of DNA topoisomerases in chromosomal replication and segregation.

J. Nitiss, 1994, Advances in pharmacology.

Recurrent mutations in topoisomerase IIα cause a previously undescribed mutator phenotype in human cancers

Arnoud Boot, S. Rozen, Willie Yu, 2022, Proceedings of the National Academy of Sciences.

Effects of an unusual poison identify a lifespan role for Topoisomerase 2 in Saccharomyces cerevisiae

G. Piazza, K. Wennerberg, D. Goldfarb, 2017, Aging.

Yeast as a tool in cancer research

J. Heitman, J. Nitiss, 2007 .

SUMO: A Swiss Army Knife for Eukaryotic Topoisomerases

Y. Pommier, Yilun Sun, J. Nitiss, 2022, Frontiers in Molecular Biosciences.

A temperature sensitive topoisomerase II allele confers temperature dependent drug resistance on amsacrine and etoposide: a genetic system for determining the targets of topoisomerase II inhibitors.

J. Nitiss, Y. Hsiung, Y. X. Liu, 1993, Cancer research.

Detection of Topoisomerase Covalent Complexes in Eukaryotic Cells.

Yilun Sun, Yang Zhao, K. C. Nitiss, 2018, Methods in molecular biology.

Mechanisms of cell killing by drugs that trap covalent complexes between DNA topoisomerases and DNA.

J. Wang, J. Nitiss, James C. Wang, 1996, Molecular pharmacology.

Yeast Tdp1 regulates the fidelity of nonhomologous end joining

K. C. Nitiss, J. Nitiss, K. Bahmed, 2010, Proceedings of the National Academy of Sciences.

Enhancing Drug Accumulation in Saccharomyces cerevisiae by Repression of Pleiotropic Drug Resistance Genes with Chimeric Transcription Repressors

G. Neale, K. C. Nitiss, J. Nitiss, 2008, Molecular Pharmacology.

A conserved SUMO pathway repairs topoisomerase DNA-protein cross-links by engaging ubiquitin-mediated proteasomal degradation

Y. Pommier, Yijun Su, Yilun Sun, 2020, Science Advances.

Repair of topoisomerase I-mediated DNA damage.

Y. Pommier, Z. Miao, C. Redon, 2006, Progress in nucleic acid research and molecular biology.

Importance of the Fourth Alpha-Helix within the CAP Homology Domain of Type II Topoisomerase for DNA Cleavage Site Recognition and Quinolone Action

K. Kohn, Y. Pommier, J. Heddle, 2002, Antimicrobial Agents and Chemotherapy.

Topoisomerase assays.

J. Nitiss, 2001, Current protocols in pharmacology.

Yeast systems for demonstrating the targets of anti-topoisomerase II agents.

K. C. Nitiss, J. Nitiss, 2001, Methods in molecular biology.

The bis(naphthalimide) DMP-840 causes cytotoxicity by its action against eukaryotic topoisomerase II.

N. Osheroff, J. Nitiss, A. Rose, 1998, Biochemistry.

Mutations in the gyrB domain of eukaryotic topoisomerase II can lead to partially dominant resistance to etoposide and amsacrine.

H. Wu, J. Nitiss, P. Vilalta, 1994, Molecular Pharmacology.

The top2-5 mutant of yeast topoisomerase II encodes an enzyme resistant to etoposide and amsacrine.

M. Jannatipour, J. Nitiss, Y. X. Liu, 1993, The Journal of biological chemistry.

Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform.

M. Sehested, J. Falck, L. Jensen, 1999, Cancer research.

Isoform α the Mutation in the Walker A Consensus ATP Binding Domain of Catalytic Inhibitor ICRF-187 Demonstrate a Functional R 162 Q Resistance to the Bisdioxopiperazine Topoisomerase II Human Small Cell Lung Cancer NYH Cells Selected for Updated

M. Sehested, J. Falck, L. Jensen, 1999 .

Kinetic Study of DNA Topoisomerases by Supercoiling-Dependent Fluorescence Quenching

M. Muller, Z. Hua, F. Leng, 2019, ACS omega.

A dual mechanism of action of the anticancer agent F 11782 on human topoisomerase II alpha.

M. Sehested, B. Hill, L. Jensen, 2003, Biochemical pharmacology.

A conserved SUMO-Ubiquitin pathway directed by RNF4/SLX5-SLX8 and PIAS4/SIZ1 drives proteasomal degradation of topoisomerase DNA-protein crosslinks

Y. Pommier, L. Jenkins, Yijun Su, 2019, bioRxiv.

The anticancer multi-kinase inhibitor dovitinib also targets topoisomerase I and topoisomerase II.

B. Hasinoff, J. Yalowich, J. Nitiss, 2012, Biochemical pharmacology.

Mutation of a conserved active site residue converts tyrosyl-DNA phosphodiesterase I into a DNA topoisomerase I-dependent poison.

M. Bjornsti, S. White, K. Babaoglu, 2007, Journal of molecular biology.

End-processing during non-homologous end-joining: a role for exonuclease 1

K. C. Nitiss, J. Nitiss, K. Bahmed, 2010, Nucleic acids research.

Interaction of Human DNA Topoisomerase II α with DNA: Quantification by Surface Plasmon Resonance†

M. Sehested, L. Jensen, A. Renodon-Cornière, 2002 .

Interaction of human DNA topoisomerase II alpha with DNA: quantification by surface plasmon resonance.

M. Sehested, L. Jensen, A. Renodon-Cornière, 2002, Biochemistry.

Human small cell lung cancer NYH cells resistant to the bisdioxopiperazine ICRF‐187 exhibit a functional dominant Tyr165Ser mutation in the Walker A ATP binding site of topoisomerase IIα

M. Sehested, A. Renodon-Cornière, P. B. Jensen, 2002, FEBS letters.

Editorial: The repair of DNA–protein crosslinks

Y. Pommier, Yilun Sun, J. Nitiss, 2023, Frontiers in Molecular Biosciences.

Twisting and Ironing: Doxorubicin Cardiotoxicity by Mitochondrial DNA Damage

K. C. Nitiss, J. Nitiss, 2014, Clinical Cancer Research.

Using energy to go downhill – a genoprotective role for ATPase activity in DNA topoisomerase II

Afif F. Bandak, J. Berger, K. C. Nitiss, 2023, bioRxiv.

Stability of the Topoisomerase II Closed Clamp Conformation May Influence DNA-stimulated ATP Hydrolysis*

M. Sehested, L. Jensen, T. Hsieh, 2005, Journal of Biological Chemistry.

Mutations of human topoisomerase II alpha affecting multidrug resistance and sensitivity.

C. Yu, A. Liu, L. Liu, 1999, Biochemistry.

TDP1 promotes assembly of non-homologous end joining protein complexes on DNA.

S. Katyal, L. Hanakahi, K. C. Nitiss, 2015, DNA repair.

A copper connection to the uptake of platinum anticancer drugs

J. Nitiss, 2002, Proceedings of the National Academy of Sciences of the United States of America.

Enhancing Drug Accumulation in Saccharomyces cerevisiae by Repression of Pleiotropic Drug Resistance Genes with Chimeric Transcription Repressors

G. Neale, K. C. Nitiss, J. Nitiss, 2008, Molecular Pharmacology.